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Conclusions: In the IMPT treatment plans calculated in this 
study, the CTV dose coverage was only slightly affected by 
setup errors and range errors. The OARs appeared to be more 
sensitive for the introduced uncertainties, with a potentially 
significant increase of dose to the OARs. 
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Purpose/Objective: To investigate the dosimetric feasibility 
of a two-steps dose escalation strategy in patients affected 
by Malignant Pleural Mesothelioma (MPM) by using Helical 
Tomotherapy (HT). 
Materials and Methods: Twelve patients with MPM, treated 
using HT, were selected. The prescribed median doses to the 
planning target volume (PTV) boost, outlined by the FDG-
PET/CT and to the PTV (pleural cavity) were 61.6 Gy (range 
60-66 Gy) and 54 Gy (range 50.4-54 Gy) in 28-30 fractions, 
respectively. PTVs and Organs At Risk (OAR) were contoured 
by physicians according to institutional protocols. Inverse 
planning optimization was performed using the following 
parameters: Field Width = 2.5 cm, pitch = 0.287, final 
Modulation Factor ranged between 1.8 and 2.3. For each 
patient two dose escalation plans were generated prescribing 
62.5 Gy and 70 Gy (2.5 and 2.8Gy/fraction respectively) to 
the PTV boost and 56 Gy (2.24 Gy/fraction) to the PTV 
pleural cavity in 25 fractions. For the three treatment 
planning strategies, for each patient, the average dose to 
controlateral lung, lungs sum, liver, heart, esophagus, 
kidneys and small bowel were evaluated. QUANTEC Dose 
Volume Histograms (DVH) constraints were used for planning 
evaluation. The statistically difference among plans was 
tested by Mann-Whitney non parametric test (MedCalc 
statistics Software). 
Results: For all plans, the 95% PTV Volumes received at least 
the 95% of the prescribed dose.  
For all the considered OARs, the dosimetric constraints 
investigated are reported in figure 1. 
 
 
Figure 1. Mean 2 Gy Equivalent Doses and standard deviation 
of OARs (α/β = 3 Gy for all organs except for heart, α/β = 2 
Gy). 
For all plan strategies the average dose to the controlateral 
lung was always below 8 Gy. There was no dosimetric 
statistically significant difference between approved and 2.5 
Gy/fr (p>0.05) while a significant dosimetric difference 
between approved and 2.8 Gy/fr average doses of OARs 
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investigated (except for kidney) was observed. However, the 
QUANTEC constraints for all plans and OARs were satisfied.  
Conclusions: The results of this study seem to demonstrate 
that it is possible to safely perform a dose escalation 
ensuring ICRU PTV indication criteria coverage and satisfying 
all QUANTEC constraints. 
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Purpose/Objective: Recent EORTC studies report an increase 
in survival in breast cancer patients treated with RT when 
the internal mammary node (IMN) is included. The 
aforementioned studies were based on conventional 3D 
irradiation with photons in breast and supraclavicular and 
axillary nodes and a direct electron field in the IMN. To our 
knowledge, the safety of including IMN in IMRT has not been 
studied to date. The objective of the study was to 
retrospectively evaluate the dosimetric impact on the usual 
organs at risk (OAR) in the irradiation of the left breast/chest 
wall (heart, lungs, and contralateral breast) treated with 
IMRT. 
Materials and Methods: We selected all breast patients (n = 
30) treated with IMRT (left breast, left chest wall, 
with/without nodes and with/without boost) in 2014. CT 
planning was performed in all patients with a Philips Big Bore 
CT. We defined the volumes to irradiate and the OAR. We 
performed a new IMRT planning to compare with the previous 
technique. We used our standard distribution of fields in each 
case. Treatment planning and volume definition were defined 
using the Eclipse V8.9 planning system from Varian. After 
optimizing dosimetry to obtain the best coverage and 
homogeneous distribution of PTVs, we compared the dose 
received in OAR for each of the 2 plans, considering the 
constraints of our service (mainly based in QUANTEC), which 
are: 
-Heart: V30<30%; V25<15; Dmean<10Gy 
-Lung: V5<60%; V20<30% 
-Ipsilateral Lung: V20<30% 
-Contralateral Lung: V5<40% 
-Contralateral Breast: V5<2% (This is an orientation constraint 
because heart and lung area priority constraint). 
We recorded the values of these indexes for IMRT with and 
without IMN. 
Results: Table 1 shows the mean values recorded for IMRT 
with and without IMN, and the differences between the two 
plans. We found a slight increase in dose in OAR when IMN 
was included, but this increase did not exceed the limits 
established in our service. 
 
 
 
Conclusions: IMN irradiation of the left breast can be safely 
performed with the new treatment techniques (IMRT) 
because it does not significantly increase the dose received 
by the OAR. 
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Purpose/Objective: The aim of this study was to compare 
the various dosimetric parameters of volumetric-modulated 
arc therapy (VMAT) for prostate cancer using a 160-leaf 
multileaf collimator (5mm-leaf, Agility) with VMAT using 80 
MLC (10mm-leaf, MLCi2). Monitor units and number of control 
points among those MLCs were also evaluated. 
Materials and Methods: Single-arc VMAT plans with Agility 
and MLCi2 were compared for 10 low to intermediate risk 
prostate cancer patients. Clinical target volume included the 
prostate and the proximal seminal vesicles. The planning 
target volume (PTV) was defined as CTV with a margin of 
5mm posterior and 8mm in other directions. The mean dose 
to PTV was 76 Gy delivered in 38 fractions. Rectums were 
contoured as solid organs from anal verge to sigmoid flexure. 
The dosimetric parameters of VMAT plans with Agility and 
MLCi2 were calculated in a Monaco treatment planning 
system for Elekta Synergy linac with Monte Carlo algorithm. 
The parameters for PTV were the near minimum dose (D98), 
the near maximum dose (D2), heterogeneity Index (HI) and 
conformity Index (CI). The parameters for rectum were V70, 
V60, V50 and V40. Monitor units and control points were also 
evaluated. Statistical analysis to evaluate the differences two 
categories was performed by the paired, two-tailed Student's 
t-test. 
Results:The mean PTV was 110.8 cc (range 70.0 to 229.4 cc). 
The mean volume of rectum was 41.9 cc (range 26.6 to 57.1 
cc). The average of the near minimum dose of PTVs (D98) 
were 71.9 Gy in Agility and 71.6 Gy in MLCi2 (P=0.02). The 
average of the near maximum dose of PTVs (D2), HI and CI 
were similar results among those MLCs. For rectum, the 
average of V70, V60, V50 and V40 in Agility were 8.56 %, 18.7 
%, 27.7% and 37.8%, respectively. The average of those 
parameters in MLCi2 were 8.72 %, 19.8 %, 29.9 % and 41.3 %, 
respectively. The average of V60, 50 and 40 in Agility was 
significantly better than those in MLCi2 (P=0.005-0.014). The 
average MUs were 452.8 in Agility and 416.9 in MLCi2, 
respectively, which showed significantly differences 
